EQ
EQ clinical trials: Equillium, Inc.
Every trial on ClinicalTrials.gov where Equillium, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 4
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
EQ on the catalyst calendar · EQ registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Apr 2027Sponsor estimate | NCT07869225A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy VolunteersEquillium · Ulcerative Colitis | EQLead | Phase 1 | Not yet recruiting | Locked | Locked | Locked |
| Apr 22, 2025Actual | NCT05263999A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)Equillium · Graft Versus Host Disease | EQLead | Phase 3 | Terminated | Locked | Locked | Locked |
| Mar 26, 2024Actual | NCT05589610Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia AreataEquillium · Alopecia Areata | EQLead | Phase 2 | Completed | Locked | Locked | Locked |
| Nov 2022Sponsor estimate | NCT03532958Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia AreataEquillium · Alopecia Areata | EQLead | Phase 2 | Withdrawn | Locked | Locked | Locked |
- Primary completion Apr 2027Sponsor estimatePhase 1NCT07869225A Phase I, Randomized, Double-Blind, Placebo-Controlled Study of EQ504 in Single and Multiple Ascending Doses in Healthy VolunteersEquillium · Ulcerative ColitisNot yet recruitingEQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 22, 2025ActualPhase 3NCT05263999A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)Equillium · Graft Versus Host DiseaseTerminatedEQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 26, 2024ActualPhase 2NCT05589610Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia AreataEquillium · Alopecia AreataCompletedEQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2022Sponsor estimatePhase 2NCT03532958Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia AreataEquillium · Alopecia AreataWithdrawnEQLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner